Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation

被引:66
作者
Nakamae, Hirohisa [1 ]
Kirby, Katharine A. [1 ]
Sandmaier, Brenda M. [1 ,2 ]
Norasetthada, Lalita [1 ]
Maloney, David G. [1 ,2 ]
Maris, Michael B. [3 ]
Davis, Chris [1 ]
Corey, Lawrence [1 ,2 ]
Storb, Rainer [1 ,2 ]
Boeckh, Michael [1 ,2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Rocky Mt Blood & Marrow Transplantat, Denver, CO USA
基金
美国国家卫生研究院;
关键词
Nonmyeloablative allogeneic hematopoietic stem cell transplantation; CMV infection; CMV diseases; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; UNRELATED DONOR STATUS; CYTOMEGALOVIRUS-INFECTIONS; HEMATOLOGIC MALIGNANCIES; IMMUNOLOGICAL RECOVERY; HOST-DISEASE; RISK-FACTORS; RECIPIENTS; THERAPY;
D O I
10.1016/j.bbmt.2009.02.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonmyeloablative conditioning is less toxic and results in initial establishment of mixed hematopoietic T cell chimerism for up to half a year with prolonged presence of host T cell immunity. In this study, we examined whether this translates into differences in the risks and/or severity of cytomegalovirus (CMV) infection and disease. We analyzed data from 537 nonmyeloablative (NM-HCT) and contemporaneous 2489 myeloablative hematopoietic cell transplant (M-HCT) recipients. In CMV seropositive recipients, no difference in the overall hazards of CMV infection at any level (adjusted hazard ratio [adj. HR] 0.9, 95% confidence interval [95% Cl]: 0.7-1.0, P=.14) was noted; however, NM-HCT was associated with a lower risk of high-grade CMV infection (adj. HR 0.7, 95% Cl: 0.5-0.9, P=.02). CMV disease rates were similar between the groups during the first 100 days after HCT, but NM-HCT recipients had an increased risk of late CMV disease (adj. HR 2.0, 95% Cl 1.2-3.4). The increased risk of late CMV disease after NM-HCT was pronounced during the earlier years of the study period, but not detectable in more recent years. Contrary to earlier reports, survival following CMV disease was not reduced after NM-HCT when compared to M-HCT recipients. These results suggest that residual host cells after NM-HCT reduce progression to higher CMV viral load in NM-HCT recipients; however, this effect does not appear to protect against serious complications of CMV. Therefore, CMV prevention strategies in NM-HCT recipients should be similar to those used in M-HCT recipients. Biol Blood Marrow Transplant 15: 694-703 (2009) (C) 2009 American Society for Blood and Marrow Transplantation
引用
收藏
页码:694 / 703
页数:10
相关论文
共 25 条
  • [1] Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning
    Baron, Frederic
    Storer, Barry
    Maris, Michael B.
    Storek, Jan
    Piette, Fanny
    Metcalf, Monja
    White, Kristen
    Sandmaier, Brenda M.
    Maloney, David G.
    Storb, Rainer
    Boeckh, Michael
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (11) : 1176 - 1187
  • [2] Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR
    Boeckh, M
    Huang, M
    Ferrenberg, J
    Stevens-Ayers, T
    Stensland, L
    Nichols, WG
    Corey, L
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (03) : 1142 - 1148
  • [3] Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
    Boeckh, M
    Leisenring, W
    Riddell, SR
    Bowden, RA
    Huang, ML
    Myerson, D
    Stevens-Ayers, T
    Flowers, MED
    Cunningham, T
    Corey, L
    [J]. BLOOD, 2003, 101 (02) : 407 - 414
  • [4] Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy
    Einsele, H
    Roosnek, E
    Rufer, N
    Sinzger, C
    Riegler, S
    Löffler, J
    Grigoleit, U
    Moris, A
    Rammensee, HG
    Kanz, L
    Kleihauer, A
    Frank, F
    Jahn, G
    Hebart, H
    [J]. BLOOD, 2002, 99 (11) : 3916 - 3922
  • [5] Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
    Einsele, H
    Hebart, H
    Kauffman-Schneider, C
    Sinzger, C
    Jahn, G
    Bader, P
    Klingebiel, T
    Dietz, K
    Löffler, J
    Bokemeyer, C
    Müller, CA
    Kanz, L
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (07) : 757 - 763
  • [6] One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation
    Erard, Veronique
    Guthrie, Katherine A.
    Varley, Cara
    Heugel, Judson
    Wald, Anna
    Flowers, Mary E. D.
    Corey, Lawrence
    Boeckh, Michael
    [J]. BLOOD, 2007, 110 (08) : 3071 - 3077
  • [7] Fenstein L, 2001, ANN NY ACAD SCI, V938, P328
  • [8] Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
    Giralt, S
    Estey, E
    Albitar, M
    vanBesien, K
    Rondon, G
    Anderlini, P
    OBrien, S
    Khouri, I
    Gajewski, J
    Mehra, R
    Claxton, D
    Andersson, B
    Beran, M
    Przepiorka, D
    Koller, C
    Kornblau, S
    Korbling, M
    Keating, M
    Kantarjian, H
    Champlin, R
    [J]. BLOOD, 1997, 89 (12) : 4531 - 4536
  • [9] CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS
    GLUCKSBERG, H
    STORB, R
    FEFER, A
    BUCKNER, CD
    NEIMAN, PE
    CLIFT, RA
    LERNER, KG
    THOMAS, ED
    [J]. TRANSPLANTATION, 1974, 18 (04) : 295 - 304
  • [10] Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study
    Junghanss, C
    Boeckh, M
    Carter, RA
    Sandmaier, BM
    Maris, MB
    Maloney, DG
    Chauncey, T
    McSweeney, PA
    Little, MT
    Corey, L
    Storb, R
    [J]. BLOOD, 2002, 99 (06) : 1978 - 1985